MicroIslet Inc. Awarded a National Institutes of Health (NIH) Grant

Published: Apr 24, 2008

SAN DIEGO--(BUSINESS WIRE)--MicroIslet, Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell transplantation therapies for diabetes, and DiaKine Therapeutics, Inc., a biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes, today announced the award of an NIH grant for “Improving porcine islet function and in vivo survival.” Under the NIH grant, MicroIslet will lead studies utilizing DiaKine’s proprietary compounds designed to develop agents capable of enhancing the immunocompatibility and survival of encapsulated porcine islets in vivo.

Back to news